2020, Number 2
Rev Cubana Hematol Inmunol Hemoter 2020; 36 (2)
Solano-Trujillo MH, Casas-Patarroyo CP, Espinosa-Redondo DL, Abello-Polo V, Parra L, Palacios A
PDF size: 345.75 Kb.
ABSTRACTIntroduction: Desmopressin is a synthetic analog for vasopressin that increases the plasma levels of factor VIII and of von Willebrand factor. Some authors indicate maintenance time of hemostatic effect between 6 and 8 hours, so it is necessary to study its effect over time.
Objective: To determine the variation of laboratory variables in patients with von Willebrand disease and type A hemophilia after desmopressin administration.
Methods: Retrospective cohort study carried out in a university hospital in Bogotá. Nonrandomized sampling was used, including 24 patients older than 18 years and with a diagnosis of von Willebrand disease (67%) and non-severe type A hemophilia (33%), who underwent the desmopressin test. Two groups of patients were created, regardless of diagnosis: 15 patients with baseline values of factor-VIII lower than 50 IU and 13 patients with baseline values of von Willebrand antigen lower than 50 IU. Descriptive and correlational statistical analysis was performed in Stata 13.
Results: 87% of patients in group I reached the therapeutic value two hours after desmopressin administration (p=0.000), which was maintained for up to six hours in 77% (p=0.000). In group II, 92% achieved the therapeutic value in two hours (p=0.003), which continued until six hours in 83% (p=0.000).
Conclusions: Response to desmopressin administration was maximum at two hours, when it began to decrease progressively, but maintained the therapeutic effect. Although no adverse effects were found, there is variability of response among patients.